Adagrasib significantly improves progression-free survival (PFS) compared to docetaxel in KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients previously treated with chemotherapy and immunotherapy.
IAG933 directly disrupts the YAP/TAZ-TEAD protein-protein interaction, leading to YAP eviction from chromatin and reduced Hippo-mediated transcription.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.